Literature DB >> 11086106

Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation.

K R Cooke1, G R Hill, A Gerbitz, L Kobzik, T R Martin, J M Crawford, J P Brewer, J L Ferrara.   

Abstract

Idiopathic pneumonia syndrome (IPS) is a major complication of allogeneic bone marrow transplantation (BMT). We have shown that experimental IPS is associated with increased levels of LPS and TNF-alpha in the bronchoalveolar lavage (BAL) fluid. We hypothesized that the deleterious effects of these inflammatory mediators in the lung may be linked to gut injury that develops after BMT. To test this hypothesis, we used mouse strains that differ in their sensitivity to LPS as donors in an experimental BMT model. Lethally irradiated C3FeB6F(1) hosts received BMT from either LPS-sensitive or LPS-resistant donors. Five weeks after BMT, LPS-resistant BMT recipients had significantly less lung injury compared with recipients of LPS-sensitive BMT. This effect was associated with reductions in TNF-alpha secretion (both in vitro and in vivo), BAL fluid LPS levels, and intestinal injury. The relationship between TNF-alpha, gut toxicity, and lung injury was examined further by direct cytokine blockade in vivo; systemic neutralization of TNF-alpha resulted in a significant reduction in gut histopathology, BAL fluid LPS levels, and pulmonary dysfunction compared with control-treated animals. We conclude that donor resistance to endotoxin reduces IPS in this model by decreasing the translocation of LPS across the intestinal border and systemic and pulmonary TNF-alpha production. These data demonstrate a potential etiologic link between gut and lung damage after BMT and suggest that methods that reduce inflammatory responses to LPS, and specifically, those that protect the integrity of the gut mucosa, may be effective in reducing IPS after BMT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086106     DOI: 10.4049/jimmunol.165.11.6612

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

2.  Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.

Authors:  Yu Yu; Dapeng Wang; Chen Liu; Kane Kaosaard; Kenrick Semple; Claudio Anasetti; Xue-Zhong Yu
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

3.  The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation.

Authors:  Senthilnathan Palaniyandi; Reena Kumari; Sabarinath Venniyil Radhakrishnan; Ethan Strattan; Natalya Hakim; Reinhold Munker; Melissa V Kesler; Gerhard C Hildebrandt
Journal:  Transplantation       Date:  2020-12       Impact factor: 4.939

4.  Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses.

Authors:  Rupali Das; Richard Komorowski; Martin J Hessner; Hariharan Subramanian; Claudia S Huettner; Daniel Cua; William R Drobyski
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

5.  Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.

Authors:  Gregory A Yanik; Mary M Horowitz; Daniel J Weisdorf; Brent R Logan; Vincent T Ho; Robert J Soiffer; Shelly L Carter; Juan Wu; John R Wingard; Nancy L Difronzo; James L Ferrara; Sergio Giralt; David K Madtes; Rebecca Drexler; Eric S White; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-07       Impact factor: 5.742

6.  Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.

Authors:  Ines A Silva; Krystyna Olkiewicz; David Askew; Jacquelyn M Fisher; Meghana N Chaudhary; Kevin M Vannella; Daphne T Deurloo; Sung W Choi; Elizabeth M Pierce; Shawn G Clouthier; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-01       Impact factor: 5.742

7.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

8.  A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Authors:  Gerhard C Hildebrandt; Krystyna M Olkiewicz; Leigh Corrion; Shawn G Clouthier; Elizabeth M Pierce; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

9.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

10.  Intestinal Microbiota of Mice Influences Resistance to Staphylococcus aureus Pneumonia.

Authors:  Stefanie Gauguet; Samantha D'Ortona; Kathryn Ahnger-Pier; Biyan Duan; Neeraj K Surana; Roger Lu; Colette Cywes-Bentley; Mihaela Gadjeva; Qiang Shan; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2015-07-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.